无缝疗法公司近日宣布,已与全球制药巨头礼来公司建立全球性研究合作伙伴关系。双方将携手开发基于可编程重组酶技术的创新疗法,旨在针对听力损失这一未满足重大医疗需求的领域取得突破。此次合作将结合无缝疗法公司在重组酶技术平台方面的专业优势与礼来在药物研发和商业化领域的丰富经验,共同推进新型疗法的研发进程。
无缝疗法公司近日宣布,已与全球制药巨头礼来公司建立全球性研究合作伙伴关系。双方将携手开发基于可编程重组酶技术的创新疗法,旨在针对听力损失这一未满足重大医疗需求的领域取得突破。此次合作将结合无缝疗法公司在重组酶技术平台方面的专业优势与礼来在药物研发和商业化领域的丰富经验,共同推进新型疗法的研发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.